CellaVision AB (STU:C26)
€ 23.1 -0.65 (-2.74%) Market Cap: 559.99 Mil Enterprise Value: 558.02 Mil PE Ratio: 44.65 PB Ratio: 8.76 GF Score: 98/100

Q3 2019 CellaVision AB Earnings Call Transcript

Oct 23, 2019 / 09:00AM GMT
Release Date Price: €29.05 (-6.44%)
Operator

Hello and welcome to the CellaVision AB Q3 Report 2019. (Operator Instructions) Today, I am pleased to present CEO, Zlatko Rihter. Please begin your meeting.

Zlatko Rihter;publ;President;CEO
CellaVision AB

()-&

Hello, and good morning, everybody. Zlatko Rihter here from Lund. I'm here together with Maria Morin, who is heading our Corporate Communications and HR; and also Magnus Blixt, who is the CFO of CellaVision. So I hope you're all doing well, and I'll take you through the quarter 3 report that we've released this morning.

So my suggestion is that now we to move to Page 3 in the presentation. And a lot -- many of you have seen this before, but just to kind of repeat the most important components of -- of our living. We see ourselves being a company that can contribute both when it comes to outcome and keywords include diagnostics and also reduced inefficiency, which eventually means reduced health care costs and thereby CellaVision, at least in the metric space or in hematology where we are

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot